Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q2 2024 · 10-Q
Revenue$95.84M$95.84M— vs Q2 2023 Net Income$49.23M$49.23MN/M vs Q2 2023 EPS Diluted$0.22$0.22N/M vs Q2 2023 Operating Income$52,087,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$116,348,000N/M Margins · derivedOperating margin54.3%
Net margin51.4%
ended Jun 30, 2024 · filed Aug 12, 2024 · 43 d after period end